Avandia

Swiss Scientists Confirm Avandia's Link to Osteoporosis

Wed, 14 May 2008 17:54:50 -0700

Swiss researchers recently concluded that Avandia, a type 2 diabetes drug, nearly doubles the chances of osteoporosis and bone fracture among patients who take the drug and is increased for patients taking the drug for more than a year. The results of the study come on heels of controversy surrounding the drug’s link to increased heart disease and various studies warning of potential risks related to bone degradation.

GlaxoSmithKline: Avandia Unlikely to Recover

Fri, 10 Aug 2007 23:03:02 -0700

The U.S. Food and Drug Administration recently voted to keep Avandia on the market. Avandia is a drug manufactured by GlaxoSmithKline and it is used to treat type 2 diabetes. However, though the news would seem positive for GlaxoSmithKline, the FDA's treatment of the situation has called into question the FDA's ability to manage situations such as these and the review likely will damage Avandia sales.

Warning Label Urged for Avandia

Thu, 09 Aug 2007 22:16:12 -0700

A U.S. Food and Drug Administration panel has concluded that diabetes patients taking the drug Avandia to treat their condition have a greater risk of heart attack than those taking other drugs to treat their conditions. While the panel did not advise removing the drug from the market, they did say that Avandia needs a stricter warning on its label.

Warning Label Urged for Avandia

Reports of Avandia-Related Heart Attacks Jumps

Thu, 09 Aug 2007 20:52:22 -0700

The side effects noted by patients taking diabetes drug Avandia tripled in the months after a study linked the drug to increased rates of heart attacks. A report from the U.S. Food and Drug Administration says: "In the 35 days after May 21, when the New England Journal of Medicine published the analysis on the Internet, reports of heart attacks, deaths and hospitalizations leaped... Only five heart attacks were reported in the 35 days before the study, compared with 90 in the same period afterward. Heart-related hospitalizations went from 11 to 126. The reports involve rosiglitazone, sold as Avandia and Avandamet."

Reports of Avandia-Related Heart Attacks Jump, Highlight Flawed FDA Monitoring

Class Action Filed Against Avandia

Wed, 08 Aug 2007 21:07:11 -0700

A class action lawsuit has been filed against GlaxoSmithKline, saying that the drug company did not do enough to alert those taking the drug of the drug's risk. The lawsuit was filed at the Court of Queen's Bench in Regina on the behalf of a 75-year-old woman who died in May after having taken Avandia.

Class Action Suit Launched Over Avandia

FDA Gave Glaxo Extra Year to Profit from Avandia

Tue, 07 Aug 2007 21:45:23 -0700

A memorandum acquired by the Senate Finance Committee shows that Food and Drug Administration knew that there were dangerous side effects associated with GlaxoSmithKline drug Avandia. The memo shows that Dr. David Ross, a FDA reviewer, recommended that there be a highlighted boxed warning on Avandia packaging about an increased risk of CHF. CHF is a life-threatening condition that occurs when fluid builds in the lungs and causes a shortness of breath.

FDA Gave Glaxo Extra Year to Profit Off Avandia

Avandia- FDA Controversy Causes Questions of Comeback

Tue, 07 Aug 2007 20:18:31 -0700

The U.S. Food and Drug Administration decided this week that GlaxoSmithKline's diabetes drug Avandia shall remain on the market, but will carry more warnings on its label. Avandia recently was linked to increased heart and kidney problems in those who take the drug to manage their diabetes. Shares of GlaxoSmithKline had their biggest gain in two years after the FDA advisory panel decided not to withdraw Avandia from the market.

Glaxo Avandia FDA Adversity Fuels Doubts of Comeback

Diabetes Drug May Cause Heart Problems

Mon, 06 Aug 2007 22:18:13 -0700

A month after a study found a possible link between heart attacks and GlaxoSmithKline's diabetes drug Avandia, the number of reported side effects tripled. Dr. Ronald Goldberg from the University of Miami Diabetes Research Institute says that diabetes patients are excited to switch medications. Goldberg says that when he explains the risks possibly associated with Avandia to patients, they "tend to feel more comfortable going off to a different medicine, a different oral medicine."

Is Avandia Safe? Depends Who You Ask.

Mon, 06 Aug 2007 19:43:14 -0700

A majority of the recent federal drug panel has voted to keep Avandia on the market. Data from recent studies have linked Avandia to increased risk of heart and kidney problems. The panel advises that Avandia remain on the market, but with more warnings on its labeling.

Is Avandia Safe? Depends Who You Talk To?

Avandia Heart Risks May Be "Inconclusive"

Fri, 13 Jul 2007 13:24:44 -0700

Researchers from the New England Journal of Medicine are reporting that data on Avandia's overall heart risks are "inconclusive." Researchers say that they have not yet established if there is an association between Avandia and heart attacks or Avandia and heart disease in general. The Food and Drug Administration says that Avadia and another diabetes drug, Actos, will be required to carry a "black box" warning about the heightened heart attack risk from taking the drug.

Avandia Heart Risks May Be "Inconclusive"

Avandia May Get Bone Warning

Thu, 12 Jul 2007 14:11:57 -0700

GlaxoSmithKline Plc's diabetes drug Avandia may soon have a warning label to consumers advising that the drug causes an increased risk of bone fractures. A recent study shows that Avandia leads to an increased risk of broken bones in women. The effect has not yet been studied in men.

Glaxo's Avandia May Get Bone Warning, Analyst Says

Congress Works to Balance Drug Safety and Fast Approval

Sat, 07 Jul 2007 14:22:59 -0700

The recent safety concerns over Vioxx, Ketek, and Avandia are highlighting the longstanding debate on how prescription medications should be approved for use by American consumers. The safety of the three drugs was called into question after the Food and Drug Administration approved them for use. Vioxx has been implicated in thousands of heart attacks, Ketek causes liver failure, and the health hazards of Avandia have only just begun to be realized.

Congress Seeks to Balance Drug Safety, Quick Approval

New Data Show Those Taking Avandia Had Lower Medical Costs

Fri, 06 Jul 2007 00:58:02 -0700

Recent data from more than 15,000 patients with type 2 diabetes show that initial therapy with Avandia was associated with significantly lower medical costs and total visits to the doctor compared to patients who were treated with a sulfonylurea. Dr. Mel Sheng Duh, the co-author of the study, said, "the study findings demonstrate that treatment with Avandia resulted in significantly lower total medical costs for the patient over time, when compared to sulfonylurea therapy. These data are important to physicians selecting treatment for their patients because the financial burden of diabetes and its associated health problems is staggering -- not only to patients but to their families and the healthcare system as well."

New Data Show Patients Treated With Avandia(R) (Rosiglitazone Maleate) Incurred Lower Medical Costs and Used Fewer Healthcare Resources When Compared to Patients Treated With Sulphonylureas

Avandia Maker Sued Over Heart Attack

Thu, 05 Jul 2007 00:29:15 -0700

Larry Alan Stanford's widow and son are suing GlaxoSmithKline, the maker of the diabetes drug Avandia. Peggie Stanford, Larry's widow, says that her husband died as a result of having taken the drug. Larry Stanford died on May 21 from a heart attack. Stanford had been taking Avandamet, a form of Avandia, combined with another diabetes drug, since early 2005.

Avandia Maker Sued Over Heart Attack

Understanding How PPAR-Gamma Agonists Work

Wed, 04 Jul 2007 12:21:32 -0700

The peroxisome proliferator-activated receptor, PPAR-gamma agonist, class of drugs is the fastest-growing class of drugs in the type 2 diabetes market. Currently, GlaxoSmithKline's Avandia and Takeda's Actos are the fastest-growing class of drugs in the type 2 diabetes market.

Understand How Recent Safety Concerns Will Affect PPAR-Gamma Agonists